Vaxcell-Bio Therapeutics Cash And Equivalents vs. Gross Profit
| 323990 Stock | KRW 10,770 630.00 5.53% |
For Vaxcell-Bio Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vaxcell-Bio Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vaxcell Bio Therapeutics Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vaxcell-Bio Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vaxcell Bio Therapeutics Co over time as well as its relative position and ranking within its peers.
Vaxcell-Bio |
Vaxcell-Bio Therapeutics Gross Profit vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Vaxcell-Bio Therapeutics's current stock value. Our valuation model uses many indicators to compare Vaxcell-Bio Therapeutics value to that of its competitors to determine the firm's financial worth. Vaxcell Bio Therapeutics Co is rated second in cash and equivalents category among its peers. It is rated below average in gross profit category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Vaxcell-Bio Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Vaxcell-Bio Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Vaxcell-Bio Gross Profit vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Vaxcell-Bio Therapeutics |
| = | 27.31 B |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Vaxcell-Bio Therapeutics |
| = | (5.39 M) |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Vaxcell-Bio Gross Profit Comparison
Vaxcell Bio is currently under evaluation in gross profit category among its peers.
Vaxcell-Bio Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Vaxcell-Bio Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Vaxcell-Bio Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Vaxcell-Bio Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Vaxcell-Bio Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea. Vaxcell Bio is traded on Korean Securities Dealers Automated Quotations in South Korea.
Vaxcell-Bio Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Vaxcell-Bio Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vaxcell-Bio Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vaxcell-Bio Therapeutics' important profitability drivers and their relationship over time.
Use Vaxcell-Bio Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vaxcell-Bio Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaxcell-Bio Therapeutics will appreciate offsetting losses from the drop in the long position's value.Vaxcell-Bio Therapeutics Pair Trading
Vaxcell Bio Therapeutics Co Pair Trading Analysis
The ability to find closely correlated positions to Vaxcell-Bio Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vaxcell-Bio Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vaxcell-Bio Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vaxcell Bio Therapeutics Co to buy it.
The correlation of Vaxcell-Bio Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vaxcell-Bio Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vaxcell-Bio Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vaxcell-Bio Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Vaxcell-Bio Therapeutics position
In addition to having Vaxcell-Bio Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Israel Wall Street Thematic Idea Now
Israel Wall Street
Cross-sector collection of best publicly traded Israel entities that are expected to continue growing. The Israel Wall Street theme has 71 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Israel Wall Street Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Vaxcell-Bio Stock
To fully project Vaxcell-Bio Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Vaxcell-Bio Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Vaxcell-Bio Therapeutics' income statement, its balance sheet, and the statement of cash flows.